Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart timing test may spot hidden vessel disease

NCT ID NCT06969547

Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a special heart scan (SPECT) can detect problems in the heart's smallest blood vessels, called microvascular dysfunction. Researchers will measure how the heart muscle moves and pumps blood in 75 people with and without coronary artery disease. The goal is to see if this scan can reliably diagnose a condition that often goes undetected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dynamic SPECT scan (diagnostic test)
What this could lead to
If successful, this could provide a new, non-invasive way to diagnose microvascular dysfunction in the heart, potentially improving detection and management.
What could go wrong
This is a small, early-stage study (75 people) focused on diagnosis, not treatment. The test may not prove accurate enough for wider use, and results may not apply to all heart disease patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Residents of Tomsk, Russia

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ischemia with no obstructive coronary arteries (INOCA) * Obstructive coronary artery disease (CAD) * Patients without evidence of coronary heart disease Exclusion Criteria: * Left ventricular ejection fraction \<55% according to echocardiography; * History of myocardial infarction/revascularization; * hypertension: systolic blood pressure \>180 mm Hg. Art., diastolic BP\>110 mm Hg. Art.; * systolic arterial hypotension \<80 mm Hg. Art.; * atrial fibrillation; * AV blockade of the III degree; sick sinus syndrome; * massive pulmonary embolism (PE) with a high degree of pulmonary hypertension; * the presence of significant valvular pathology (mitral insufficiency ≥ 3 degrees, aortic insufficiency ≥ 3 degrees, tricuspid regurgitation ≥ 3 degrees). * severe course of bronchial asthma, chronic obstructive pulmonary disease; * decompensated type 2 diabetes, * severe liver or kidney failure (glomerular filtration rate \<50 ml/min/1.73 m3 (CKD-EPI), * morbid obesity (body mass index \>45); * history of myocarditis * indications of poor drug tolerance; * oncological diseases; * chronic alcoholism, mental disorders; * other severe comorbidity, * refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic ischemic heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia nonobstructive coronary artery disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD) Mechanical dyssynchrony Myocardial blood flow reserve

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tomsk NRMC Cardiology Research Institute

    RECRUITING

    Tomsk, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.